Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002).

NCT04687982 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

19

Enrollment

OTHER

Sponsor class

Conditions

Bone Marrow Transplant Infection
Bone Marrow Transplant Complications
Graft Vs Host Disease
Infection
Hematological Malignancy

Interventions

BIOLOGICAL: modified donor lymphocytes infusion (mDLI)

Sponsor

Istituto Clinico Humanitas